Material Event (Form 8-K)

On April 7, 2026, Galera Therapeutics, Inc. (the "Company") converted 76,479.175 shares of the Company's Series B Non-VotingConvertible Preferred Stock, par value $0.001 per share ("Series B Preferred Stock"), into 76,479,164 shares of the Company's common stock, par value $0.001 per share ("Common Stock"), pursuant to and in accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-VotingConvertible Preferred Stock, as amended (the "Certificate of Designation"). No fractional shares of Common Stock were issued in connection with the partial mandatory conversion; in lieu of any fractional shares, the Company will pay each holder an amount in cash equal to the trading value of such fractional shares as of the close of business on the date of the conversion in accordance with the Certificate of Designation. Following the conversion, 42,839.11 shares of Series B Preferred Stock remain issued and outstanding.

In addition, on April 8, 2026, certain affiliates of Ikarian Capital, LLC exercised a portion of their pre-fundedwarrants to purchase an aggregate of 8,488,229 shares of Common Stock at an exercise price of $0.001 per share, and the related aggregate exercise price of approximately $8,488.23 was paid to the Company. Following the exercise, pre-fundedwarrants to purchase an additional 14,552,811 shares of Common Stock remain outstanding.